Neumora Therapeutics Reports Positive Interim Data from Phase 1b Trial of NMRA-511 in Rare Neurological Disorder

Neumora Therapeutics Inc (NMRA) has released interim findings from its Phase 1b clinical trial evaluating NMRA-511, a novel investigational therapy targeting a rare, monogenic neurodegenerative disorder. The study enrolled 18 adult patients across multiple dose cohorts, with data collected over a 12-week treatment period. All participants received oral administration of NMRA-511 at escalating doses ranging from 10 mg to 60 mg once daily. The nut graph reveals that NMRA-511 demonstrated a favorable safety profile, with no dose-limiting toxicities reported. Adverse events were mostly mild to moderate, including transient gastrointestinal disturbances and mild fatigue. No serious adverse events or treatment-related discontinuations occurred. Pharmacokinetic analysis confirmed dose-proportional exposure, with plasma concentrations reaching steady state by Week 4. Biomarker assessments also indicated early signs of target engagement, with a 32% reduction in disease-specific metabolites observed in the highest dose cohort. Key metrics from the trial include a 78% patient retention rate at Week 12 and consistent dosing adherence across all cohorts. These outcomes support progression to a larger, randomized Phase 2 trial, which Neumora plans to initiate in the second half of 2026. The company has also filed an investigational new drug (IND) application in the U.S. for a potential pediatric extension study. The data are expected to influence investor sentiment around NMRA’s pipeline, particularly among biotechnology-focused funds and small-cap health sector investors. Stock trading activity for NMRA has increased by 11% over the past three days following the announcement, reflecting heightened interest in the company’s development trajectory.